WCLC 2025 - Posters & ePosters-EP.12.46 Efficacy of Sunvozertinib in Advanced NSCLC With HER2 Exon 20 Insertion After Prior Treatment Failure: A Real-World Case Series

EP.12.46 Efficacy of Sunvozertinib in Advanced NSCLC With HER2 Exon 20 Insertion After Prior Treatment Failure: A Real-World Case Series

Back to course

Pdf Summary

This real-world case series evaluates the efficacy and safety of sunvozertinib, a novel tyrosine kinase inhibitor (TKI), in treating advanced non-small cell lung cancer (NSCLC) patients harboring HER2 exon 20 insertion mutations after prior treatment failures. HER2 exon 20 insertions define an aggressive NSCLC subset with limited therapeutic options and poor prognosis.<br /><br />The retrospective analysis included three female patients aged 48 to 59 years with adenocarcinoma at clinical stages IIIA to IIIC. All had undergone previous treatments ranging from one to five lines, including chemotherapy, immunotherapy, and other TKIs. Each patient received 300 mg of sunvozertinib once daily.<br /><br />Treatment responses were promising: two patients achieved partial responses with tumor shrinkage of 40%, while one patient maintained stable disease with a 10% reduction in tumor size. Treatment durations ranged from four to nine months. Adverse events reported were manageable and primarily included diarrhea, rash, mucositis, and decreased appetite.<br /><br />These findings demonstrate that sunvozertinib can produce meaningful clinical benefit even in heavily pretreated NSCLC patients with HER2 exon 20 insertions. The drug’s tolerable safety profile further supports its utility in this setting.<br /><br />In conclusion, the case series suggests that sunvozertinib is a promising therapeutic option for advanced NSCLC patients harboring HER2 exon 20 insertion mutations who have progressed after prior treatments. The authors advocate for further prospective studies to validate these encouraging real-world results.

Asset Subtitle

Liu Dongying

Meta Tag

Speaker Liu Dongying

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

sunvozertinib

tyrosine kinase inhibitor

TKI

non-small cell lung cancer

NSCLC

HER2 exon 20 insertion

adenocarcinoma

treatment efficacy

adverse events

real-world study